endpts.com Open in urlscan Pro
65.9.95.93  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN



Inman Pharmacy owner Mike Reppucci says reimbursements on GLP-1s often come in
below the cost to acquire the drugs. (Nicole DeFeudis for Endpoints News)
October 31, 2023 10:30 AM EDTUpdated 03:22 PM
Health Tech


LO­CAL PHAR­MA­CIES SAY THEY'RE STRUG­GLING TO AF­FORD GLP-1S


NICOLE DEFEUDIS

EDITOR

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up,
just click here.)

Har­ry Webb has seen a flur­ry of in­ter­est in pop­u­lar weight loss drugs at
his in­de­pen­dent phar­ma­cies in In­di­ana, but he doesn’t know how much
longer he can af­ford to stock them.

Many lo­cal phar­ma­cies are los­ing mon­ey on glucagon-like pep­tide-1 (GLP-1)
re­cep­tor ag­o­nists like No­vo Nordisk’s Ozem­pic and We­govy as
re­im­burse­ment rates come in be­low ac­qui­si­tion cost, ac­cord­ing to an
in­for­mal sur­vey from the Na­tion­al Com­mu­ni­ty Phar­ma­cists
As­so­ci­a­tion. Re­spon­dents re­port­ed los­ing an av­er­age of more than $37
per 30-day sup­ply, ac­cord­ing to the un­pub­lished sur­vey. 


UNLOCK THIS ARTICLE INSTANTLY BY BECOMING A FREE SUBSCRIBER.

You’ll get access to free articles each month, plus you can customize what
newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER


TRENDING NOW


VER­TEX DOESN’T NEED TO DO MORE TEST­ING FOR ROGUE GENE ED­ITS FROM SICK­LE CELL
THER­A­PY TRI­AL, FDA AD­VI­SORS SAY


AS­TRAZENECA PAYS $25M UP­FRONT, $80M EQ­UI­TY IN­VEST­MENT IN­TO CEL­LEC­TIS
FOR GENE AND CELL THER­A­PY PACT


PFIZ­ER SHELVES FIVE MID- AND EAR­LY-STAGE PRO­GRAMS


GEN­ER­A­TIVE AI BIOTECH PART­NERS WITH CAN­CER CEN­TER IN BID TO SPEED UP CAR-T
DE­VEL­OP­MENT IN SOL­ID TU­MORS


GSK TOUTS AREXVY SALES AS IT DOM­I­NATES US OLD­ER ADULT RSV MAR­KET, COM­PA­NY
CUTS THREE EAR­LY-STAGE AS­SETS

sponsored


THE RARE KID­NEY DIS­EASE PLAY­BOOK: HOW NEW RE­SEARCH AND IN­NO­VA­TION IS
TRANS­FORM­ING THE RKD TREAT­MENT LAND­SCAPE

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



Healthcare

ENDPOINTS HEALTH TECH Coming soon


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.